Fusion protein of an exendin to modified transferrin

US8158579B2 · kind B2 · utility

Assignee

• Biorexis Pharmaceutical Corporation · US

Inventors

• David J. Ballance · Berwyn, US
• Christopher P. Prior · Rosemont, US
• Homayoun Sadeghi · Doylestown, US
• Andrew J. Turner · King of Prussia, US

Key dates

• Filing date: Nov 30, 2010
• Grant date: Apr 17, 2012
• Expiry date: Nov 30, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/03
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.